更为重要的是，通过CD40L这种东西增强的TIL细胞更像是“干细胞”，可以有更加持久的抗癌能力。目前美国莫菲特癌症中心正在开展一项临床试验，以检测这个方法在非小细胞肺癌患者的应用，也就是说CD40L增强型TIL有望能成为下一代TIL疗法的标准。

上面的这个图表来自本文的参考文献，看起来花花绿绿比较难以看懂。这里咱们只是用来佐证研究者的结论：他们使用一种名为CD40L的东西，可以将肿瘤病灶里提取的TIL培养效率提升，没有使用CD40L则TIL只在33%的样本里成功生长，而使用CD40L则TIL ...

Eledon Pharmaceuticals, Inc.’s ELDN share price has surged by 7.68%, which has investors questioning if this is right time to ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

The key is a natural immune protein called CD40L. “We discovered that by adding CD40L to the immune cells in the lab, we could dramatically improve the number and quality of cancer-fighting T cells we ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L is an attractive drug development target for transplant ...

TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand. Shares of Tonix Pharmaceuticals are up 3% in pre-market trade on Wednesday.

About NG-350A NG-350A is a clinical-stage, intravenously delivered T-SIGn® therapeutic designed to drive intratumoral expression of a CD40 agonist monoclonal antibody triggering the activation of ...